ArticleScientific reports2025
A transcriptomic and proteomic analysis and comparison of human brain tissue from patients with and without epilepsy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- AAV-mediated GPR173 gene therapy attenuates long-term refractory epilepsy by enhancing synaptic GABAActa pharmacologica Sinica · 2026Article
- Diverse Roles of Tubulin Polymerization Promoting Protein 3 (TPPP3) in Human Health and Disease.Cells · 2025Review
- Single-cell sequencing reveals cellular heterogeneity and molecular mechanisms in tendon and enthesis injury repair.Frontiers in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study was to investigate potential biomarkers and therapeutic targets for epilepsy by conducting a transcriptomic and proteomic analysis of human brain tissue from patients with epileptic lesions. Brain tissue was collected from the epileptic lesions after surgical resection and surgical removed brain tissue from non-epileptic patients. Using RNA sequencing and iTRAQ-based proteomic analysis, The transcriptomic analysis identified 1,604 DEGs, with 584 upregulated and 1,020 downregulated. The proteomic analysis identified 694 DEPs, with 331 upregulated and 363 downregulated. The combined transcriptomic and proteomic analysis showed that the DEGs and DEPs were mainly enriched in biological processes such as D-aspartate transport, transmembrane transport, cell junctions, vesicle transport, and metabolic processes. Tubulin polymerization promoting protein family member-3 (TPPP3), proprotein convertase subtilisin/kexin type-1 (PCSK1), and dihydropyrimidinase-like 3 (DPYSL3) were significantly altered in the epilepsy patients, and their expression trends were confirmed by the RT-qPCR, WB, and IHC staining results. By integrating transcriptomic and proteomic analyses, we identified genes and proteins expressed differently in epileptic and non-epileptic patients and their associated biological processes. Three key DEPs (TPPP3, PCSK1, and DPYSL3) were identified, indicating their potential significance in the pathological mechanisms of epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.